Effectiveness Of Helium in reducing symptoms of Autism Spectrum Disorder

Efficacy of potentized Helium versus individualised Homoeopathic medicine in reducing the symptoms of Autism Spectrum disorder in children - A single blind randomised control trial.

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2022/10/046521

Enrollment

Registered

2022-10-17

Start date

Unknown

Completion date

Unknown

Last updated

2022-11-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: F840- Autistic disorder

Interventions

Intervention1: Homoeopathic Medicines: Individualised Homoeopathic medicines in potencies and dosage as per requirement will be prescribed orally according to the Homoeopathic principles. Duration of

Eligibility

Inclusion criteria

Inclusion criteria: Age group between 2-16 years, Subjects of both sexes, Cases satisfying Autism Spectrum Disorder diagnostic criteria of DSM 5 , Having minimum ISAA SCALE score of 40 0r >40

Exclusion criteria

Exclusion criteria: Diagnosed cases of chromosomal abnormalities. Diagnosed cases of Intellectual Disability. Other comorbid psychiatric illness.

Design outcomes

Primary

Measure	Time frame
To determine the efficacy of potentized Helium vs individualized homoeopathic medicine in reducing the symptoms of Autism Spectrum disorder in children using ISAA scaleTimepoint: 6 months - Enrolment period 1 Year - follow up period	—

Secondary

Measure	Time frame
1.To evaluate the treatment outcome using ATEC scale. 2. Reverification of the symptoms of Helium obtained from provings. Timepoint: 6 months - Enrolment period 1 Year - follow up period	—

Countries

India

Contacts

Public ContactDr M Gnnanaprakasham

National HomoeopathyResearch institute in Mental Health

drgprakashpsy@gmail.com9444701176

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026